![]() | ![]() |
Formats:
|
||||||||||||||||||||||||||||||||||||||
Copyright © 2007 The Authors. Journal compilation © 2007 The Physiological Society Bidirectional shifts of TRPM8 channel gating by temperature and chemical agents modulate the cold sensitivity of mammalian thermoreceptors Alicante Institute of Neuroscience, University Miguel Hernández-CSIC Corresponding author A. Mälkiä: Instituto de Neurociencias de Alicante, Universidad Miguel Hernández-Consejo Superior de Investigaciones Cientificas (CSIC), Apartado 18, San Juan de Alicante 03550, Spain. Email: annika.malkia/at/umh.es Received November 22, 2006; Accepted February 16, 2007. This article has been cited by other articles in PMC.Abstract TRPM8, a member of the melastatin subfamily of transient receptor potential (TRP) cation channels, is activated by voltage, low temperatures and cooling compounds. These properties and its restricted expression to small sensory neurons have made it the ion channel with the most advocated role in cold transduction. Recent work suggests that activation of TRPM8 by cold and menthol takes place through shifts in its voltage-activation curve, which cause the channel to open at physiological membrane potentials. By contrast, little is known about the actions of inhibitors on the function of TRPM8. We investigated the chemical and thermal modulation of TRPM8 in transfected HEK293 cells and in cold-sensitive primary sensory neurons. We show that cold-evoked TRPM8 responses are effectively suppressed by inhibitor compounds SKF96365, 4-(3-chloro-pyridin-2-yl)-piperazine-1-carboxylic acid (4-tert-butyl-phenyl)-amide (BCTC) and 1,10-phenanthroline. These antagonists exert their effect by shifting the voltage dependence of TRPM8 activation towards more positive potentials. An opposite shift towards more negative potentials is achieved by the agonist menthol. Functionally, the bidirectional shift in channel gating translates into a change in the apparent temperature threshold of TRPM8-expressing cells. Accordingly, in the presence of the antagonist compounds, the apparent response-threshold temperature of TRPM8 is displaced towards colder temperatures, whereas menthol sensitizes the response, shifting the threshold in the opposite direction. Co-application of agonists and antagonists produces predictable cancellation of these effects, suggesting the convergence on a common molecular process. The potential for half maximal activation of TRPM8 activation by cold was ~140 mV more negative in native channels compared to recombinant channels, with a much higher open probability at negative membrane potentials in the former. In functional terms, this difference translates into a shift in the apparent temperature threshold for activation towards higher temperatures for native currents. This difference in voltage-dependence readily explains the high threshold temperatures characteristic of many cold thermoreceptors. The modulation of TRPM8 activity by different chemical agents unveils an important flexibility in the temperature–response curve of TRPM8 channels and cold thermoreceptors. Transient receptor potential (TRP) channels comprise an extensive family of cation-permeable channels found in animals and fungi. More than 30 members have been identified in mammals, with a wide expression profile (Montell et al. 2002; Clapham, 2003). Targeted gene deletions of several TRP channels have revealed some of their key physiological functions, which include pheromone sensory signalling (TRPC2), innocuous heat sensation (TRPV3), osmoregulatory responses (TRPV4), taste transduction (TRPM5) and nociception (TRPV1 and TRPA1) (for references, see original publications by Caterina et al. 2000; Bautista et al. 2006; Kwan et al. 2006; and reviews by Fleig & Penner, 2004; Wissenbach et al. 2004; Desai & Clapham, 2005; Pedersen et al. 2005; Nilius et al. 2007). Many TRP channels have polymodal activation and several are thought to play important roles in somatosensory thermal transduction (reviewed by Jordt et al. 2003; McKemy, 2005; Dhaka et al. 2006). TRPM8 is a non-selective calcium-permeable TRP channel that is activated by cold and menthol, and is postulated to play a critical role in the transduction of moderate cold stimuli that give rise to cool sensations (McKemy et al. 2002; Peier et al. 2002; Reid, 2005; Voets et al. 2007). TRPM8 has a limited expression profile in the nervous system, restricted to a subpopulation of primary sensory neurons of small diameter in dorsal root and trigeminal ganglia (McKemy et al. 2002; Peier et al. 2002). Most cold-sensitive neurons are excited by both cooling and menthol (Reid & Flonta, 2001; McKemy et al. 2002; Viana et al. 2002; Thut et al. 2003), and also express TRPM8 mRNA transcripts (Nealen et al. 2003). Moreover, many cold-sensitive neurons express a non-selective cation current (Icold) with biophysical and pharmacological properties consistent with the properties of TRPM8-dependent currents in transfected cells (Okazawa et al. 2002; Reid et al. 2002). In addition, TRPM8 has been found in prostate tissue, where its physiological function remains uncertain (Tsavaler et al. 2001; Zhang & Barritt, 2006). Although TRP channels were originally thought to be voltage independent, it now seems that several of them exhibit weak voltage dependence (Hofmann et al. 2003; Nilius et al. 2003, 2005; Brauchi et al. 2004; Voets et al. 2004). In the case of TRPM8, the voltage dependence manifests as activation upon depolarization to positive transmembrane potentials, and a rapid and voltage-dependent closure at negative potentials (Brauchi et al. 2004; Voets et al. 2004). Cooling shifts the activation curve of TRPM8 towards more negative potentials, and thus increases the probability of channel openings at physiological membrane potentials. A similar shift is induced by the cooling agent menthol, causing the channel to activate at temperatures above 30°C (Voets et al. 2004). Despite the important physiological functions of TRP channels, knowledge about their biophysical properties is still modest compared to that of other ion channels (Owsianik et al. 2006) and pharmacological tools to study or modulate them are very limited (Desai & Clapham, 2005; Dhaka et al. 2006). A notable exception is the pharmacology of the heat- and vanilloid-activated channel TRPV1, which has expanded significantly in the past few years (Garcia-Martinez et al. 2002; Valenzano et al. 2003; Krause et al. 2005). By contrast, reports on means to regulate TRPM8 activity are scarce and incomplete. Recent studies show that ethanol inhibits TRPM8 function at concentrations of the order of 0.5–3% (Weil et al. 2005; Benedikt et al. 2007). In addition, a number of known TRPV1 antagonists have been tested on heterologously expressed TRPM8 channels, such as the complex between the divalent copper ion and 1,10-phenanthroline (Cu–Phe), capsazepine, 4-(3-chloro-pyridin-2-yl)-piperazine-1-carboxylic acid (4-tert-butyl-phenyl)-amide (BCTC) and the related thio-BCTC and (2R)-4-C3-chloro-2-pyridinyl)-2-methyl- N-[4-(trifluoromethyl)phenyl]-1-piperazinecarboxamide (CTPC), the urea derivative SB-452533 and the cinnamide derivative SB-366791 (Behrendt et al. 2004; Weil et al. 2005; Madrid et al. 2006). With the exception of BCTC and ethanol, studies with these antagonists have been limited to responses evoked by application of menthol at constant room temperature – a mixture of chemical and physiological stimuli – thereby revealing little information about the nature and mechanism of the inhibition. Furthermore, almost nothing is known about the actions of these or other TRPM8 blockers on native thermoreceptors. In many cases, the lack of specific blockers prevents or impairs a proper functional characterization of the channel in physiological systems. The availability of selective and potent TRPM8 channel antagonists is an essential tool in clarifying the role of different ion channels in thermal responses of intact cold receptors. In addition, modulators of TRPM8 activity have significant therapeutic potential in the treatment of prostate cancer (Zhang & Barritt, 2006). Here, we studied SKF96365, BCTC and 1,10-phenanthroline for their blocking effects on cold-activated TRPM8 responses. BCTC and SKF96365, which exhibited high antagonist potency, were subsequently characterized with respect to their mechanism of inhibition; results suggest a similar but opposite mode of action to that of menthol. The results obtained on recombinant channels were verified on native cold thermoreceptors. Methods Cloning of TRPM8 in pcINeo/IRES–GFP Transfection of HEK293 cells with TRPM8 was carried out using the recombinant bicistronic expression plasmid pcINeo–TRPM8–IRES–GFP, which carries the protein-coding region of rat TRPM8 (accession number, AY072788) and the green fluorescent protein (GFP) coupled by an internal ribosomal entry site (IRES) sequence. GFP fluorescence could thus be used to identify TRPM8-expressing cells. The bicistronic vector pcINeo–IRES–GFP was provided by Jan Eggermont (Katholieke Universiteit Leuven, Belgium) and pcDNA3–TRPM8 was made available by David Julius (University of California, San Francisco, CA, USA). The new construct was verified by automatic sequencing. Cell culture HEK293 cells were obtained from the European Collection of Cell Cultures (Salisbury, UK). Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum and antibiotics, and plated in 2 cm × 2 cm wells at 4–5 × 105 cells well−1. Next, 20–24 h after plating, the cells were transfected with the TRPM8–IRES–GFP construct by incubating them with a solution containing the plasmid DNA (2 μg well−1) and Lipofectamine 2000 (Invitrogen; 3 μl well−1) for 4–6 h. Subsequently, the cells were trypsinized and replated on laminin-coated round coverslips (12 mm diameter) at 8–10 × 104 cells coverslip−1. GFP-positive cells were selected for calcium-imaging or electrophysiology experiments 20–72 h after transfection. HEK293 cells stably expressing rat TRPM8 channels (CR#1 cells) were kindly provided by Ramón Latorre (Center for Scientific Studies, Valdivia, Chile). They were cultured as described in by Brauchi et al. (2004). All experimental procedures concerning animals were carried out according to the Spanish Royal Decree 223/1988 and the European Community Council directive 86/609/EEC. Trigeminal ganglion neurons from neonatal mice were cultured as previously described (de la Pena et al. 2005). In brief, newborn Swiss OF1 mice (postnatal day 1–5) were anaesthetized with ether and decapitated. The trigeminal ganglia were isolated and incubated with 1 mg ml−1 collagenase type IA, and cultured in a medium containing 45% DMEM, 45% F-12 and 10% fetal calf serum (Invitrogen), supplemented with 4 mml-glutamine (Invitrogen), 200 μg ml−1 streptomycin, 125 μg ml−1 penicillin, 17 mm glucose and nerve growth factor (NGF, mouse 7S, 100 ng ml−1, Sigma-Aldrich, Madrid, Spain). Cells were plated on poly-l-lysine-coated glass coverslips and used after 1–3 days in culture. Calcium imaging The calcium imaging experiments were conducted with the fluorescent indicator Fura-2. Prior to each experiment, the cells were incubated with 5 μm acetoxymethylester form of Fura-2 (Molecular Probes Europe, the Netherlands) for 45 min at 37°C. Fluorescence measurements were made with a Zeiss Axioskop FS (Germany) upright microscope fitted with an ORCA ER CCD camera (Hamamatsu, Japan). Fura-2 was excited at 340 and 380 nm (excitation time, 200 or 300 ms) with a rapid switching monochromator (TILL Photonics, Germany), and the emitted fluorescence was filtered with a 510 nm long-pass filter. Mean fluorescence intensity ratios (F340/F380) were displayed on-line with Axon Imaging Workbench or Metafluor software (Molecular Devices, PA, USA). The calcium imaging experiments were performed simultaneously with temperature recordings. The bath solution, referred to as ‘control solution’, contained (mm): NaCl 140, KCl 3, CaCl2 2.4, MgCl2 1.3, Hepes 10 and glucose 10, and was adjusted to pH 7.4 with NaOH. Electrophysiology Whole-cell voltage-clamp recordings were performed simultaneously with temperature recordings. Standard patch pipettes (3–5 MΩ) were made of borosilicate glass capillaries (Harvard Apparatus Ltd, UK) and contained (mm): CsCl 140, MgCl2 0.6, EGTA 1 and Hepes 10; 278 mosmol kg−1, pH adjusted to 7.4 with CsOH. In Icold threshold experiments, the internal solution contained (mm): KCl 140, NaCl 6, MgCl2 0.6, EGTA 1, NaATP 1, NaGTP 0.1 and Hepes 10; 282 mosmol kg−1, pH adjusted to 7.4 with KOH). The bath solution used was the same as in the calcium imaging experiments. For whole-cell recordings in trigeminal neurons, patch pipettes had a resisitance of 7–8 MΩ. To measure the activation of Icold in neurons, the bath solution contained (mm): NaCl 140, KCl 3, MgCl2 1.3, CaCl2 0.1, Hepes 10, glucose 10 and TTX 0.5 × 10−3; pH was adjusted to 7.4 with NaOH. The pipette solution contained (mm): CsCl 140, MgCl2 0.6, EGTA 1, Hepes 10, ATPNa2 1 and GTPNa 0.1; pH was adjusted to 7.4 with CsOH. These modifications were necessary to minimize large voltage-dependent currents. Current signals were recorded with an Axopatch 200B patch-clamp amplifier (Molecular Devices). Stimulus delivery and data acquisition were performed using pCLAMP9 software (Molecular Devices). Chemical modulators The chemical substances studied for their modulatory effect on TRPM8 were the cooling agent l-menthol (Scharlau, Spain), and the antagonists 1,10-phenanthroline (Sigma), SKF96365 (Tocris Bioscience, Bristol, UK) and BCTC which was a kind gift from Grünenthal GmbH Aachen (Germany). Temperature stimulation Coverslips with cultured cells were placed in a microchamber and continuously perfused with solutions warmed to 32–34°C. The temperature was adjusted with a water-cooled Peltier device placed at the inlet of the chamber, and controlled by a feedback device. Cold sensitivity was investigated with a temperature drop to 15–18°C (see Fig. 1E
Experimental protocols and interpretation of results During calcium-imaging experiments, the effects of the antagonist compounds were investigated with a protocol, wherein a first cooling stimulus in control solution was followed by a second one in the presence of a blocking agent (see Fig. 2A and B
We also used whole-cell recordings of cold-induced currents to investigate the action of the different antagonists on TRPM8 channel activity. For dose–inhibition correlations, blocker compounds were briefly applied during an extended cold stimulus (see Fig. 2D and E
To provide information on shifts in the threshold temperatures, a protocol similar to that used for calcium imaging was used, where responses to cold in the presence and absence of antagonists were recorded at a holding potential of −60 mV. To estimate the shifts in the voltage dependence of activation of TRPM8 in HEK293 cells, current–voltage (I–V) relationships obtained from repetitive (0.2 Hz) voltage ramps (−100 to +200 mV, 525 ms duration) were fitted with a function that combines a linear conductance multiplied by a Boltzmann activation term (Nilius et al. 2006):
Using voltage ramps instead of steps involves the possibility of not working under steady-state conditions. The benefit of the ramp protocol is, nevertheless, that it is more rapid, thus minimizing the time-dependent rundown of the current. We performed control experiments where we applied voltage ramps at two different speeds (525 ms and 5 s duration) in the same cells. No statistically significant difference was observed between the fitting parameters at the two speeds. However, we do not rule out the possibilty that the absolute values of the parameters may be slightly affected by non-stationary conditions. Data analysis Data are reported as mean ± standard error of the mean. The apparent threshold temperatures were estimated as the first point at which the measured signal (F340/F380 or current) deviated by at least four times the standard deviation of its baseline. Data were analysed with WinASCD written by Dr Guy Droogmans (ftp://ftp.cc.kuleuven.ac.be/pub/droogmans/winascd.zip) and Origin 7.0 (OriginLab Corporation). Fitting was carried out with the Levenberg–Marquardt method implemented in Origin 7.0 software. In dose–response fits, the standard errors of the mean were used as weights. When comparing two means, statistical significance (P < 0.05) was assessed by Student's two-tailed t test. For multiple comparison of means obtained in the same subjects, one-way repeated-measures ANOVA was performed using GraphPad Prism version 4.00 for Windows (San Diego, CA, USA, http://www.graphpad.com). Results Co-transfection with TRPM8 and GFP Analysis of 25 separate calcium-imaging experiments, with a total of 107 GFP-expressing HEK293 cells, revealed that 88% of these responded to a cold stimulus (Fig. 1A–D Cold-evoked responses in TRPM8-transfected HEK293 cells From electrophysiology experiments, we determined a mean apparent threshold temperature of TRPM8 in HEK293 cells in control solution of 27.6 ± 0.5°C (n = 19), when the temperature was lowered from a base value of 32–33°C at a holding potential of −60 mV. In the calcium-imaging experiments, the apparent threshold temperature was 26.8 ± 0.1°C (n = 641). The threshold distribution in the calcium-imaging experiments exhibited a range of 13°C and a median value of 27.0°C (see Fig. 1F When two subsequent cooling stimuli were carried out, as shown in Fig. 1H SKF96365, BCTC and 1,10-phenanthroline block cold-evoked responses in TRPM8-expressing HEK293 cells SKF96365 is a non-specific blocker of various calcium-permeable channels, including both receptor-operated and voltage-gated types, as well as those activated by internal calcium store depletion (Merritt et al. 1990). At higher concentrations (IC50, ~40 μm), SKF96365 has also been reported to block an inwardly rectifying K+ current in endothelial cells (Schwarz et al. 1994). In dorsal root ganglion neurons, a cold-activated current was reduced by almost 70% in the presence of 100 μm SKF96365 (Reid et al. 2002). We tested the effects of SKF96365 on cold-evoked responses in TRPM8-transfected HEK293 cells. As shown in Fig. 2A In the whole-cell electrophysiology experiments, various concentrations of SKF96365 (0.1–20 μm) were applied during an extended cooling stimulus (Fig. 2D BCTC was recently introduced as an orally bioavailable antagonist agent of the TRPV1 channel, with a high selectivity in an extensive radioligand screen against other ion channels (Valenzano et al. 2003). More recent studies demonstrate that BCTC also readily blocks menthol-evoked (Behrendt et al. 2004; Weil et al. 2005) and cold-evoked responses of TRPM8 (Madrid et al. 2006). We tried to establish BCTC as a reference compound of TRPM8 block, comparing its effects on TRPM8 with those of other drugs. A typical calcium-imaging recording is shown in Fig. 2B Cu–Phe is an oxidizing agent capable of inducing formation of disulphide bridges between appropriately located thiol groups, and has been widely employed in studies of the gating motion of voltage-gated channels (Liu et al. 1996). The Cu–Phe complex is also an antagonist of the TRPV1 channel; however, in this case it acts as an open-channel blocker instead of inducing cysteine cross-linking (Tousova et al. 2004). Meanwhile, both the free 1,10-phenanthroline and its Cu–Phe complex are equally potent open-channel blockers of the human skeletal muscle Na+ channel (Popa & Lerche, 2006). In our studies, the free 1,10-phenanthroline acted as an antagonist of the TRPM8-mediated cold-evoked responses in HEK293 cells. The dose–response data of 1,10-phenanthroline block from calcium-imaging and whole-cell electrophysiology experiments were fitted to the Hill equation (Fig. 2C and F Blockade of Icold by BCTC and SKF96365 is voltage dependent The nature of the antagonism of cold-evoked currents of TRPM8 by BCTC and SKF96365 was studied in more detail with whole-cell electrophysiology. As seen in Fig. 3A and D
The I–V data were further employed to construct dose–inhibition curves at different potentials. As the cold-evoked inward current was often very small, analysis at negative potentials was less accurate, and thus the potentials +20 and +100 mV were chosen for illustrative purposes. For BCTC, shown in Fig. 3C The inhibition of the cold-evoked current by 1,10-phenanthroline was also voltage dependent (not shown), exhibiting weaker inhibition at more positive potentials. The effect was quantified for 600 μm 1,10-phenanthroline, which blocked 92 ± 2% of the cold-evoked current at +40 mV, and 70 ± 2% at +100 mV (P < 0.001, Student's paired t test, n = 3). BCTC and SKF96365 shift the activation curve of TRPM8 towards more positive potentials The voltage-dependent antagonism by BCTC and SKF96365, together with the fact that both compounds are electroneutral at pH 7.4, led us to think that they are not acting as typical pore blockers driven by the transmembrane voltage (Hille, 2001). Recently it was shown that low temperature and menthol activate TRPM8 channels by producing a shift in the voltage-dependence of activation towards more negative potentials (Voets et al. 2004; Brauchi et al. 2004). We hypothesized that the mechanism of inhibition exerted by the studied TRPM8 antagonists involved an opposite effect on the voltage dependence of activation (i.e. a shift in gating towards more depolarized potentials). Consequently, TRPM8 activation was probed with 525 ms duration voltage ramps from −100 to +200 mV in whole-cell voltage-clamp mode both in CR#1 HEK293 cells stably expressing rat TRPM8 channels (Brauchi et al. 2004) and in transiently transfected HEK293 cells (Fig. 4A, B, D and E
Figure 4A A summary of the mean values obtained for the fitting variables under different experimental conditions is shown in Table 1. As reported previously, cooling and menthol produced marked leftward shifts in V1/2 (Voets et al. 2004; Brauchi et al. 2004). By contrast, application of 3 μm BCTC produced a positive shift in V1/2 and a reduction in g but no apparent change in the slope factor s (P > 0.05 when comparing conditions with and without BCTC). For conditions of 33°C, 20°C, 100 μm menthol at 33°C, and 100 μm menthol at 20°C, application of 3 μm BCTC shifted V1/2 by 34 ± 9 mV (n = 6); 67 ± 11 mV (n = 8); 78 ± 6 mV (n = 21), and 97 ± 11 mV (n = 15), respectively (P < 0.05 for all shifts, paired t test). These data indicate that the inhibitory effects of BCTC increase under conditions of high open probability of the TRPM8 channel.
To better illustrate the bidirectional shifts in the voltage activation of TRPM8 induced by BCTC, menthol and temperature, we constructed a summary histogram (Fig. 4C We subsequently studied whether a similar effect on the voltage activation of TRPM8 was induced by SKF96365 and 1,10-phenanthroline. Figure 4D and E The functional consequence of the bidirectional shift in channel gating is a displacement in the apparent temperature-response threshold of TRPM8-expressing cells The observation that the antagonists and menthol shift the activation curve of TRPM8 in opposite directions prompted us to investigate whether the same holds true for the apparent response threshold during a temperature stimulus. Figure 5A
For SKF96365 we found, similarly, that the apparent response threshold was shifted to lower temperature values in the presence of antagonist. From whole-cell electrophysiology experiments (Fig. 6A and B
Expressing the average threshold-temperature shifts as divided by unit concentration, one obtains −7.2 and −2.6°C μm−1 for BCTC and SKF96365, respectively, yielding a ratio of potency of 2.8 in favour of BCTC. It is intriguing that by comparing the shifts in V1/2 induced by the two antagonists (8.1 and 22.4 mV μm−1), one obtains exactly the same ratio, suggesting that the two phenomena are strongly coupled. These results indicate that, with regard to cold sensing, the main functional effect of the antagonists is a dose-dependent shift in the apparent temperature activation threshold of the cell. The modulation of cold-evoked responses of TRPM8-expressing cells by menthol and antagonists is additive Considering the opposite shifts in activation curves and apparent temperature thresholds induced by menthol and the antagonists, we were curious to investigate the effects of joint applications of agonists (thermal and chemical) and antagonists on TRPM8 channel activity. Menthol-evoked responses of TRPM8 have previously been shown to be blocked by BCTC (Behrendt et al. 2004; Weil et al. 2005; Madrid et al. 2006). We confirmed the same to be true for SKF96365 (not shown), with 20 μm of the antagonist blocking 99.5 ± 3% of the calcium response evoked by 100 μm menthol (n = 12, P < 0.001, paired t test). To obtain quantitative information on the menthol-induced shifts in temperature sensitivity of TRPM8, we constructed a dose–threshold shift curve (Fig. 7A and B
Figure 7C We subsequently searched our data for menthol and antagonist concentrations for which matching threshold temperature shifts, but in the opposite direction, had been observed during individual applications, to see whether these shifts could be cancelled out during the combined application of both agents. Figure 7E Bidirectional modulation by menthol and blocking agents on cold-evoked responses are maintained in trigeminal thermoreceptors We investigated whether similar bidirectional shifts in channel function can be observed in native cold thermoreceptors, the sensory neurons responsible for the transduction and coding of temperature signals in the peripheral nervous system (Hensel, 1981). Cold-sensitive trigeminal ganglion neurons were identified by calcium imaging as previously described (de la Pena et al. 2005). During rapid reductions in bath temperature from a baseline of 34°C to approximately 18°C, cold-sensitive neurons responded with an average [Ca2+]i elevation of 247 ± 44 nm (n = 20) exhibiting a mean apparent threshold of 30.2 ± 0.9°C with a range of 10°C. This threshold temperature is significantly higher than the one we obtained in TRPM8-expressing HEK293 cells (P < 0.001, Student's unpaired t test). All cold-sensitive neurons identified in this particular calcium-imaging screen were also activated by menthol, which suggests they all expressed endogenous TRPM8 channels. We note here that in a previous similar screen with a higher number of neurons, we also identified a cold-sensitive but menthol-insensitive population that represented ~8% of the total number of cold-sensitive neurons (Madrid et al. 2006). In these neurons, 3 μm BCTC strongly suppressed [Ca2+]i increases evoked by cold and completely abolished the responses to 100 μm menthol at 34°C (Fig. 8A and C
Finally, the effects of agonists and antagonists on native Icold activation were also investigated. As shown in Fig. 8D The effects of BCTC on the voltage activation of Icold were further studied with application of −100 to +200 mV ramps from a holding potential of −60 mV (Fig. 9A
To estimate V1/2, the ramp I–V data obtained in the presence and absence of antagonists were fitted (red lines in Fig. 9C
These results indicate that native cold-sensitive channels with similar biophysical properties to TRPM8 (e.g. similar reversal potential and rectification properties) are activated by temperature at more negative membrane potentials. The native channels are blocked by BCTC in a similar manner to recombinant TRPM8 in terms of amplitude, but the biophysical modulation (shifts in V1/2 and temperature threshold) underlying the inhibition is notably stronger in the trigeminal neurons. Discussion At present very little is known about the pharmacological and biophysical properties of TRPM8 channel antagonists (Desai & Clapham, 2005; Dhaka et al. 2006; Voets et al. 2007). This information is essential to better understand the role of TRPM8 channels in temperature transduction at peripheral thermoreceptors (Madrid et al. 2006). In this study, we provide a thorough characterization of the responses of recombinant TRPM8 channels to their physiological stimulus, cold temperature, and describe in mechanistic terms the effects of substances that increase and decrease the temperature sensitivity of the channel. We identified a common modulatory action of three chemical antagonists (BCTC, SKF96365 and 1,10-phenanthroline) on TRPM8 function that involves marked shifts in their voltage-dependent gating. Furthermore, we describe important differences between the properties of recombinant TRPM8 channels and native currents in trigeminal cold thermoreceptors that underlie their high thermal sensitivity. Cold-induced responses in TRPM8-expressing HEK293 cells and trigeminal neurons In our experiments, rat TRPM8-transfected HEK293 cells responded to cooling with apparent threshold temperatures of 26.8°C and 27.6°C as measured by calcium imaging and electrophysiology, respectively. These values, although among the highest reported for heterologously expressed rodent TRPM8 (McKemy et al. 2002; Peier et al. 2002; Andersson et al. 2004), are clearly lower than observed for cold-sensitive trigeminal and dorsal root ganglion neurons (Reid et al. 2002; Viana et al. 2002; Thut et al. 2003; Madrid et al. 2006). Such differences suggest that the cellular environment (e.g. membrane lipid composition and presence of auxiliary subunits) may be an important factor in the modulation of TRPM8 function, and/or that other mechanisms of cold transduction are present in sensory neurons, making them more sensitive to temperature decreases (de la Pena et al. 2005). BCTC is the most potent antagonist of cold-evoked responses in TRPM8 channels Arranging the blockers from our study by their IC50 values yielded the following sequence of potency: BCTC > SKF96365 >> 1,10-phenanthroline, with the first two compounds exhibiting concentrations of half-maximum TRPM8 inhibition below or close to 1 μm. Comparison with previously reported values revealed that SKF96365 is a slightly more potent antagonist of TRPM8 than of other TRP channels (e.g. TRPC3 and TRPC6) studied to date (Zhu et al. 1998; Inoue et al. 2001). By contrast, SKF96365 was not an effective blocker of the epithelial calcium channel TRPV5 (Nilius et al. 2001). Here, 1,10-phenanthroline was equally effective in blocking cold-evoked TRPM8 responses in the presence as in the absence of Cu2+. This finding is in contrast with a previous report on TRPV1, where heat-evoked currents were only blocked in the presence of the Cu–Phe complex (Tousova et al. 2004) suggesting a different mechanism of block for these two TRP channels. BCTC produced full antagonism of cold-evoked TRPM8 activity in the temperature range studied, with similar IC50 values to those determined using menthol as the stimulus (Behrendt et al. 2004; Weil et al. 2005; Madrid et al. 2006). These IC50 values, although one to two orders of magnitude larger than observed for TRPV1 (Valenzano et al. 2003; Correll et al. 2004), make BCTC the most potent and most effective antagonists of TRPM8 channels to date. In conclusion, although none of the blockers studied here are specific for TRPM8, the potent and reversible TRPM8 antagonism by BCTC and SKF96365 should make them useful for further functional characterization of thermoreceptor fibres and the role of TRPM8 channels in cold transduction. Menthol and the blockers act as TRPM8 modulators in opposite directions TRPM8 is a voltage-dependent channel (Voets et al. 2004; Brauchi et al. 2004; Rohacs et al. 2005). Low temperature, cooling agents (such as menthol) and the inositide phospholipids (such as phosphatidylinositol 4,5-bisphosphate (PIP2)) are known to shift the activation curve towards more physiological membrane potentials. However, the mechanisms and sites of action of these stimuli on the TRPM8 protein remain unclear. The voltage and temperature sensors are situated on separate structural domains (Brauchi et al. 2006). Furthermore, the menthol binding site and the cold sensor are structurally separate entities (Bandell et al. 2006). Whether the menthol molecule acts directly on the voltage sensor of TRPM8 or has a separate binding site on the protein remains to be resolved. In the present work, we identify three new gating modifiers of TRPM8. On basis of the apparent voltage dependence of block and the shifts in the voltage activation of the channel towards more depolarized potentials, BCTC, SKF96365 and 1,10-phenanthroline should be considered negative allosteric modulators of the channel. In agreement with this view, recent reports on the effects of ethanol (albeit at a high concentration) on TRPM8 were also ascribed to a rightward shift in voltage-dependent gating (Benedikt et al. 2007). These agents may become useful tools in the ongoing quest for the molecular determinants of TRPM8 gating and regulation (Chuang et al. 2004; Nilius et al. 2005; Rohacs et al. 2005; Bandell et al. 2006). It is also of interest to find out whether the heat-sensitive TRPV1 channel can be modulated in a similar way by these chemical agents. The main functional consequence of the dynamic voltage-dependent gating of TRPM8 is a shift in the apparent temperature activation threshold of the cell. Consequently, the studied antagonists exert an opposite effect to cooling and menthol on the thermosensitivity of the channel. Furthermore, the effects induced separately by menthol and the antagonists appear to be additive (i.e. they cancel each other during joint application of the compounds). The above findings raise the question of whether menthol and the antagonists studied here share the same site of action, or act through separate receptors. We find indications suggesting that the antagonists may be acting on different sites from which they exert their competitive, opposite effects on the voltage gating of TRPM8. Because the functional and biophysical effects of the antagonists on cold-evoked responses – shifts in apparent temperature thresholds and V1/2 – take place both in the absence and presence of menthol, and the antagonist-induced shifts in the voltage-dependent activation are in fact stronger during activation by menthol than by cold, it seems likely that the inhibitory effect is independent of the occupation of the menthol-binding site. This issue can only be completely settled with a direct analysis of ligand binding, with ad hoc designed radioactive probes. The fact that none of the inhibitors acted as a pure pore blocker (i.e. reducing channel activity without affecting channel gating) indicates that some caution should be taken when interpreting the lack of inhibitory actions of these agents on cold-evoked responses at nerve terminals (Madrid et al. 2006): the negative modulatory effects on the native channel may be insufficient to prevent cold-evoked activity. However, when we compared the effects of BCTC on channel gating observed in TRPM8-expressing HEK293 cells and in cold-sensitive trigeminal neurons, we found that the opposite was true: the neurons were, in fact, more sensitive to modulation by BCTC than the HEK293 cells. Together with the fact that in the study by Madrid et al. (2006) the effects of menthol – a more potent agonist of recombinant TRPM8 channels than cold temperature – were fully suppressed at the nerve terminals, the new observations from this work argue for alternative explanations, such as the presence of additional, TRPM8-independent, cold sensors at nerve endings (Viana et al. 2002). Native Icold channels have distinct properties The bidirectional modulation of the voltage-dependent activation and the resulting shift in temperature threshold caused by menthol and antagonists is also conserved in cold-sensitive trigeminal neurons expressing native TRPM8 protein subunits. We found a remarkable difference in the V1/2 of TRPM8 activation between native and recombinant channels, with a much higher open probability at negative potentials in the former case. Thus, despite lower values of cold- and menthol-sensitive conductance in neurons (i.e. lower density of TRPM8 channels), their higher open probability gives rise to larger inward currents at physiological membrane potentials. In functional terms, this difference translates into a much higher apparent threshold temperature in native thermoreceptors compared to recombinant TRPM8 channels (see Supplementary Fig. 1). In both cases, response thresholds can be shifted bidirectionally by more than 15°C, directly illustrating the dynamic nature of the apparent temperature threshold of TRPM8 channels. Although our results were obtained with exogenous agents, it is very likely that endogenous modulators of the channel operate upon the same general principles, and in the process give rise to the wide range of threshold temperatures exhibited by recombinant TRPM8 channels in various expression systems (de la Pena et al. 2005) and cold-sensitive thermoreceptors (Reid et al. 2002; Viana et al. 2002; Thut et al. 2003). One such endogenous modulator could be the membrane lipid PIP2, which is known to potentiate the activity of TRPM8 (Liu & Qin, 2005; Rohacs et al. 2005; Benedikt et al. 2007) and that of other TRP channels (Hardie, 2003; Nilius et al. 2006). Notably, PIP2 modulates TRPM8 by shifting the V1/2 of activation of the channels (Rohacs et al. 2005). Additional factors that may contribute to the response plasticity of thermoreceptors are changes in TRPM8 channel density, modulation of TRPM8 by intracellular Ca2+ levels (McKemy et al. 2002; Reid et al. 2002; Rohacs et al. 2005), phosphorylation status of TRPM8 (Premkumar et al. 2005; Abe et al. 2006) and the variable expression of potassium channels acting as temperature-dependent excitability brakes (Viana et al. 2002). Acknowledgments The authors thank E. Quintero, A. Miralles and A. Pérez Vegara for excellent technical assistance. The TRPM8 cDNA and pcINeo-IRES-GFP vector were generous gifts from Drs David Julius and Jan Eggermont, respectively. The HEK293 CR#1 cell line was supplied by Dr Ramón Latorre. The authors thank Diego Muñoz for performing some preliminary experiments concerning effects of BCTC. During the course of this work A.m. was supported by the Spanish Ministry of Foreign affairs (MAE)/Spanish Agency for International Cooperation (AECI), the Osk Huttunen Foundation and the Academy of Finland (grant no. 107866), R.m. was supported by a postdoctoral fellowship of the Spanish Fundación Marcelino Botín and V.M and M.V. by predoctoral fellowships from the Generalitat Valenciana. The work was also supported by funds from the Spanish Ministry of Education and Science: projects SAF2004-01011 to F.V. and BFI2002-03788 to C.B. Online supplemental material for this paper can be accessed at: http://jp.physoc.org/cgi/content/full/jphysiol.2006.123059/DC1 and http://www.blackwell-synergy.com/doi/suppl/10.1113/jphysiol.2006.123059 Supplemental data
References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||||||||||||||||||
Cell. 2002 Mar 8; 108(5):595-8.
[Cell. 2002]Nature. 2003 Dec 4; 426(6966):517-24.
[Nature. 2003]Science. 2000 Apr 14; 288(5464):306-13.
[Science. 2000]Cell. 2006 Mar 24; 124(6):1269-82.
[Cell. 2006]Neuron. 2006 Apr 20; 50(2):277-89.
[Neuron. 2006]Nature. 2002 Mar 7; 416(6876):52-8.
[Nature. 2002]Cell. 2002 Mar 8; 108(5):705-15.
[Cell. 2002]Pflugers Arch. 2005 Oct; 451(1):250-63.
[Pflugers Arch. 2005]Handb Exp Pharmacol. 2007; (179):329-44.
[Handb Exp Pharmacol. 2007]Nature. 2001 Oct 4; 413(6855):480.
[Nature. 2001]Curr Biol. 2003 Jul 1; 13(13):1153-8.
[Curr Biol. 2003]J Biol Chem. 2003 Aug 15; 278(33):30813-20.
[J Biol Chem. 2003]J Physiol. 2005 Aug 15; 567(Pt 1):35-44.
[J Physiol. 2005]Proc Natl Acad Sci U S A. 2004 Oct 26; 101(43):15494-9.
[Proc Natl Acad Sci U S A. 2004]Nature. 2004 Aug 12; 430(7001):748-54.
[Nature. 2004]Annu Rev Physiol. 2006; 68():685-717.
[Annu Rev Physiol. 2006]Pflugers Arch. 2005 Oct; 451(1):11-8.
[Pflugers Arch. 2005]Annu Rev Neurosci. 2006; 29():135-61.
[Annu Rev Neurosci. 2006]Proc Natl Acad Sci U S A. 2002 Feb 19; 99(4):2374-9.
[Proc Natl Acad Sci U S A. 2002]J Pharmacol Exp Ther. 2003 Jul; 306(1):377-86.
[J Pharmacol Exp Ther. 2003]Endocr Relat Cancer. 2006 Mar; 13(1):27-38.
[Endocr Relat Cancer. 2006]Proc Natl Acad Sci U S A. 2004 Oct 26; 101(43):15494-9.
[Proc Natl Acad Sci U S A. 2004]J Physiol. 2005 Sep 1; 567(Pt 2):415-26.
[J Physiol. 2005]EMBO J. 2006 Feb 8; 25(3):467-78.
[EMBO J. 2006]Nature. 2004 Aug 12; 430(7001):748-54.
[Nature. 2004]Biochem Biophys Res Commun. 1999 Jul 14; 260(3):712-7.
[Biochem Biophys Res Commun. 1999]Biochem J. 1990 Oct 15; 271(2):515-22.
[Biochem J. 1990]Cell Calcium. 1994 Jan; 15(1):45-54.
[Cell Calcium. 1994]J Physiol. 2002 Dec 1; 545(Pt 2):595-614.
[J Physiol. 2002]J Pharmacol Exp Ther. 2003 Jul; 306(1):377-86.
[J Pharmacol Exp Ther. 2003]Br J Pharmacol. 2004 Feb; 141(4):737-45.
[Br J Pharmacol. 2004]Mol Pharmacol. 2005 Aug; 68(2):518-27.
[Mol Pharmacol. 2005]J Neurosci. 2006 Nov 29; 26(48):12512-25.
[J Neurosci. 2006]Neuron. 1996 Apr; 16(4):859-67.
[Neuron. 1996]Neuropharmacology. 2004 Aug; 47(2):273-85.
[Neuropharmacology. 2004]Br J Pharmacol. 2006 Apr; 147(7):808-14.
[Br J Pharmacol. 2006]Neuron. 1996 Apr; 16(4):859-67.
[Neuron. 1996]J Biol Chem. 2002 Nov 8; 277(45):42719-25.
[J Biol Chem. 2002]Nature. 2002 Mar 7; 416(6876):52-8.
[Nature. 2002]Nature. 2004 Aug 12; 430(7001):748-54.
[Nature. 2004]Nature. 2004 Aug 12; 430(7001):748-54.
[Nature. 2004]Proc Natl Acad Sci U S A. 2004 Oct 26; 101(43):15494-9.
[Proc Natl Acad Sci U S A. 2004]Nature. 2004 Aug 12; 430(7001):748-54.
[Nature. 2004]Nature. 2004 Aug 12; 430(7001):748-54.
[Nature. 2004]Proc Natl Acad Sci U S A. 2004 Oct 26; 101(43):15494-9.
[Proc Natl Acad Sci U S A. 2004]Br J Pharmacol. 2004 Feb; 141(4):737-45.
[Br J Pharmacol. 2004]Mol Pharmacol. 2005 Aug; 68(2):518-27.
[Mol Pharmacol. 2005]J Neurosci. 2006 Nov 29; 26(48):12512-25.
[J Neurosci. 2006]Nature. 2004 Aug 12; 430(7001):748-54.
[Nature. 2004]Monogr Physiol Soc. 1981; 38():1-321.
[Monogr Physiol Soc. 1981]J Physiol. 2005 Sep 1; 567(Pt 2):415-26.
[J Physiol. 2005]J Neurosci. 2006 Nov 29; 26(48):12512-25.
[J Neurosci. 2006]Pflugers Arch. 2005 Oct; 451(1):11-8.
[Pflugers Arch. 2005]Annu Rev Neurosci. 2006; 29():135-61.
[Annu Rev Neurosci. 2006]Handb Exp Pharmacol. 2007; (179):329-44.
[Handb Exp Pharmacol. 2007]J Neurosci. 2006 Nov 29; 26(48):12512-25.
[J Neurosci. 2006]Nature. 2002 Mar 7; 416(6876):52-8.
[Nature. 2002]Cell. 2002 Mar 8; 108(5):705-15.
[Cell. 2002]J Neurosci. 2004 Jun 9; 24(23):5364-9.
[J Neurosci. 2004]J Physiol. 2002 Dec 1; 545(Pt 2):595-614.
[J Physiol. 2002]Nat Neurosci. 2002 Mar; 5(3):254-60.
[Nat Neurosci. 2002]J Biol Chem. 1998 Jan 2; 273(1):133-42.
[J Biol Chem. 1998]Circ Res. 2001 Feb 16; 88(3):325-32.
[Circ Res. 2001]Br J Pharmacol. 2001 Oct; 134(3):453-62.
[Br J Pharmacol. 2001]Neuropharmacology. 2004 Aug; 47(2):273-85.
[Neuropharmacology. 2004]Br J Pharmacol. 2004 Feb; 141(4):737-45.
[Br J Pharmacol. 2004]Mol Pharmacol. 2005 Aug; 68(2):518-27.
[Mol Pharmacol. 2005]J Neurosci. 2006 Nov 29; 26(48):12512-25.
[J Neurosci. 2006]J Pharmacol Exp Ther. 2003 Jul; 306(1):377-86.
[J Pharmacol Exp Ther. 2003]Neurosci Lett. 2004 Nov 3; 370(1):55-60.
[Neurosci Lett. 2004]Nature. 2004 Aug 12; 430(7001):748-54.
[Nature. 2004]Proc Natl Acad Sci U S A. 2004 Oct 26; 101(43):15494-9.
[Proc Natl Acad Sci U S A. 2004]Nat Neurosci. 2005 May; 8(5):626-34.
[Nat Neurosci. 2005]J Neurosci. 2006 May 3; 26(18):4835-40.
[J Neurosci. 2006]Nat Neurosci. 2006 Apr; 9(4):493-500.
[Nat Neurosci. 2006]J Neurochem. 2007 Jan; 100(1):211-24.
[J Neurochem. 2007]Neuron. 2004 Sep 16; 43(6):859-69.
[Neuron. 2004]J Physiol. 2005 Aug 15; 567(Pt 1):35-44.
[J Physiol. 2005]Nat Neurosci. 2005 May; 8(5):626-34.
[Nat Neurosci. 2005]Nat Neurosci. 2006 Apr; 9(4):493-500.
[Nat Neurosci. 2006]J Neurosci. 2006 Nov 29; 26(48):12512-25.
[J Neurosci. 2006]Nat Neurosci. 2002 Mar; 5(3):254-60.
[Nat Neurosci. 2002]J Physiol. 2005 Sep 1; 567(Pt 2):415-26.
[J Physiol. 2005]J Physiol. 2002 Dec 1; 545(Pt 2):595-614.
[J Physiol. 2002]Nat Neurosci. 2002 Mar; 5(3):254-60.
[Nat Neurosci. 2002]Neuroscience. 2003; 119(4):1071-83.
[Neuroscience. 2003]J Neurosci. 2005 Feb 16; 25(7):1674-81.
[J Neurosci. 2005]